- Report
- April 2025
- 307 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- January 2026
- 180 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 487 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- May 2025
- 118 Pages
Global
From €5036EUR$5,750USD£4,371GBP
- Report
- July 2025
- 350 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- September 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- February 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- May 2024
- 200 Pages
Global
From €3635EUR$4,150USD£3,155GBP
- Report
- February 2024
- 119 Pages
Global
From €4160EUR$4,750USD£3,611GBP

Rubidium-82 (Rb-82) is a radioactive isotope used in Nuclear Medicine and Radiopharmacology. It is produced through the irradiation of natural rubidium with a cyclotron, and is used in the diagnosis and treatment of cardiovascular diseases. Rb-82 is used in positron emission tomography (PET) imaging, which is a non-invasive imaging technique used to detect and diagnose diseases. It is also used in myocardial perfusion imaging, which is a type of imaging used to assess the function of the heart.
Rb-82 is a short-lived isotope with a half-life of only 1.27 minutes, making it ideal for use in Nuclear Medicine and Radiopharmacology. It is also relatively inexpensive compared to other isotopes used in Nuclear Medicine.
Companies in the Rubidium-82 market include GE Healthcare, Bracco Imaging, Mallinckrodt Pharmaceuticals, and Lantheus Medical Imaging. Show Less Read more